Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 14/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | MELK | Q14680 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5477450 | 0.97 | F2 (0.39) | F2METAP2PRSS1PRSS2PRSS3 | |
| SCHEMBL8292991 | 0.90 | F2 (0.38) | F2MELKJAK2JAK1TYK2 | |
| SCHEMBL5474422 | 0.85 | F2 (0.37) | F2METAP2PRSS1PRSS2PRSS3 | |
| SCHEMBL5483406 | 0.79 | ALOX5AP (0.39) | F2 | |
| SCHEMBL7026286 | 0.77 | F2 (0.45) | F2PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL7018692 | 0.77 | F2 (0.45) | F2PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL7020182 | 0.77 | F2 (0.45) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5484745 | 0.76 | ATM (0.39) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8293958 | 0.75 | F2 (0.42) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8293357 | 0.74 | F2 (0.41) | F2PRSS1JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099927-A1 | Aminoalkyl-pyrazinones and-pyridones as thrombin inhibitors | F2, F12, SERPINC1 | F2 1/4885METAP2 891/4885MELK 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.